Cornerstone Therapeutics Provides 2010 Financial Guidance

Friday, January 8, 2010 Corporate News
Email Print This Page Comment
Font : A-A+

Key Financial Metrics

$ million (except per share)

2010

In excess of

Net Revenue

$112

GAAP  income from operations

$1.0

Non-GAAP income from operations(1)

$ 16.4

GAAP net  income

$0.6

Non-GAAP net income(2)

$10.2

GAAP net income per share, diluted

$ 0.02

Non-GAAP net income per share, diluted(3)

$ 0.38

(1) Non-GAAP income from operations is a non-GAAP financial measure that excludes expected stock-based compensation ($1.0 million) and amortization of product rights ($14.4 million).

(2) Non-GAAP net income is a non-GAAP financial measure that excludes expected stock-based compensation ($1.0 million) and amortization of product rights ($14.4 million) and the income tax effects of these items totaling $9.6 million.

(3) Non-GAAP net income per share, diluted is a non-GAAP financial measure that is calculated as non-GAAP net income divided by the diluted weighted-average common shares. Based on our current estimates, we have assumed that we will have 26.6 million diluted weighted-average common shares outstanding during 2010.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook